OncBioMune Mexico

OncBioMune Mexico is a clinical-stage biopharmaceutical company and a subsidiary of OncBioMune Pharmaceuticals, dedicated to the development of innovative cancer immunotherapies. The company's lead program is ProVax, a therapeutic vaccine for prostate cancer that combines a recombinant protein (PSA) with a biological adjuvant to trigger a targeted immune response without the toxicity associated with chemotherapy. OncBioMune established its presence in Mexico through the acquisition of Vitel S.A. de C.V., a move intended to facilitate Phase 2 and Phase 3 clinical trials and provide a commercial bridge to the Latin American market. Despite promising early-stage data and a portfolio of licensed products, the company's operations have stalled following financial difficulties at the parent level.